The invention provides isolated primate cells preferably human cells that comprise a genetically engineered disruption in a human leukocyte antigen (HLA) class II-related gene, which results in deficiency in MHC class II expression and function. This invention also provides isolated cells further comprising a genetically engineered disruption in a beta-2 microglobulin (B2M) gene, which results in HLA class I/class II deficiency. Also provided are the method of using the cells for transplantation and treating a disease condition.

There is described herein, a method for inducing Tc22 lineage T cells from a population of CD8+ T cells, the method comprising: a) providing a population of CD8+ T cells; b) activating the population; and c) culturing or contacting the population of CD8+ T cells with Coenzyme A.

The invention is generally directed to a method of enhancing proliferation of T regulatory cells (Tregs) in vitro, comprising contacting Tregs with cells (I), or conditioned medium from the cells, in the presence of one or more Treg stimulation agents. The Treg stimulation agent(s) is present in an amount and for a time effective to stimulate proliferation of the Tregs. The cells (I) are present in an amount and for a time effective to enhance proliferation of the Tregs. The cells (I) are non-embryonic stem, non-germ cells characterized by one or more of the following: extended replication in culture and express markers of extended replication, express markers of pluripotentiality, and have broad differentiation potential, are not tumorigenic or transformed, and have a normal karyotype. The invention is also directed to methods for immune modulation using the proliferated Tregs, cell banks, drug discovery methods, populations, and compositions of the proliferated Tregs.

Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.

The invention covers the use of certain classes of lipids including cationic lipids in ex-vivo dendritic cell therapies. The cationic lipids enhance antigen uptake, processing and presentation of the processed antigens by dendritic cells to CD8+and CD4+T-cells via the MHC classes I and II presentation pathways respectively. Antigen uptake via cationic lipid by dendritic cells result in significant lowering of the population of the immune suppressive regulatory T cells in the tumors and a significant increase of the tumor targeting cytotoxic T-cells. Loss of regulatory T cells and increase of tumor specific cytotoxic cells are conducive to effective elimination of the tumors.

The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

Described herein are constructs used for B-cell genomic engineering and for expression of a transgene and/or for modulation of B cell function.

Provided herein are compositions and methods related to the treatment of multiple sclerosis in a subject.

Disclosed herein include methods of inducing expansion of modified effector cells in vivo which comprise administration of a steroid and modified effector cells. Also described herein include methods of inducing expansion of modified T cells (e.g., CAR-T cells or TCR cells) in vivo, which comprise administration of a steroid and modified T cells.

The present invention relates to a pharmaceutical preparation for treating an inflammatory condition, preferably a condition associated with ischemia comprising: a) a physiological solution comprising peripheral blood mononuclear cells (PBM-Cs) or a subset thereof, or b) a supernatant of the solution a), wherein the solution a) is obtainable by cultivating PBMCs or a subset thereof in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h.